<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892024000100007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Alteraciones de la hemostasia en pacientes graves con hemopatías malignas: trastornos trombóticos]]></article-title>
<article-title xml:lang="en"><![CDATA[Altered haemostasis in critically ill patients with blood malignancies: thrombotic disorders]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Acosta]]></surname>
<given-names><![CDATA[Zuzet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Figueroa Saez]]></surname>
<given-names><![CDATA[Juan Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Hematología e Inmunología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>40</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892024000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892024000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892024000100007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La enfermedad trombótica asociada a las hemopatías malignas es subestimada en el paciente grave; en ocasiones queda a la sombra de las hemorragias que presentan estos enfermos. Su diagnóstico y tratamiento constituyen un desafío para lograr el aumento de la sobrevida en las unidades de cuidados críticos  Objetivos:  Analizar los aspectos generales de las alteraciones trombóticas en pacientes graves con hemopatías malignas.  Métodos:  Se realizó una investigación bibliográfico-documental acerca del tema. Se consultaron en las bases de datos de SciELO y Pubmed, los artículos publicados en los últimos diez años.  Análisis y síntesis de la información:  Se describen los aspectos generales vinculados con el mecanismo de la coagulación, sus criterios diagnósticos; así como la evolución del paciente con trombosis que ingresan en las unidades de cuidados intensivos.  Conclusiones:  El conocimiento de las alteraciones tromboembólicas en los pacientes con hemopatías malignas permite un monitoreo adecuado y la creación de estrategias individuales para mejorar la sobrevida de estos enfermos en la la unidad de cuidados intensivos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Thrombotic disease associated with malignant hemopathies is underestimated in critically ill patients; sometimes it remains in the shadow of the hemorrhages that these patients present. Its diagnosis and treatment constitute a challenge to achieve increased survival in these patients in critical care units  Objectives:  To analyze the general aspects of thrombotic alterations in seriously ill patients with malignant hemopathies.  Methods:  A bibliographical-documentary research on the subject was carried out. The SciELO and Pubmed databases of the last ten years were consulted.  Analysis and synthesis of the information:  General aspects related to the coagulation mechanism, its diagnostic criteria are described; as well as the evolution of the patient with thrombosis who is admitted to the intensive care unit.  Conclusions:  Knowledge of thromboembolic alterations in patients with malignant hemopathies allows adequate monitoring and the creation of individual strategies to improve the survival of these patients in the ICU.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[trombosis]]></kwd>
<kwd lng="es"><![CDATA[paciente grave]]></kwd>
<kwd lng="es"><![CDATA[hemopatías malignas]]></kwd>
<kwd lng="es"><![CDATA[hemostasia]]></kwd>
<kwd lng="en"><![CDATA[thrombosis]]></kwd>
<kwd lng="en"><![CDATA[critically ill patient]]></kwd>
<kwd lng="en"><![CDATA[malignant hemopathies]]></kwd>
<kwd lng="en"><![CDATA[haemostasis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Legere]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dweik]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Arróliga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Venous thromboembolism in the intensive care unit]]></article-title>
<source><![CDATA[Clin Chest Med]]></source>
<year>1999</year>
<volume>20</volume>
<page-range>367-83</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Cruz]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Legere]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Takao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Arróliga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Tromboembolismo venoso en cuidados intensivos. 50 años, 50 temas]]></source>
<year>1999</year>
<conf-name><![CDATA[ VICongreso Panamericano e Ibérico de Medicina Crítica y Terapia Intensiva]]></conf-name>
<conf-loc> </conf-loc>
<page-range>380-94</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trousseau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phlegmasia alba dolens]]></article-title>
<source><![CDATA[Clinique Medicale de l&#8217;Hotel Dieu de Paris]]></source>
<year>1865</year>
<edition>2nd</edition>
<page-range>654-712</page-range><publisher-loc><![CDATA[Paris ]]></publisher-loc>
<publisher-name><![CDATA[Baillière]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahajan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brunson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wun]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Epidemiology of Cancer-Associated Venous Thromboembolism An Update]]></article-title>
<source><![CDATA[Semin Thromb Hemost]]></source>
<year>2019</year>
<volume>45</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>321-5</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Winter]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Dorresteijn]]></surname>
<given-names><![CDATA[JAN]]></given-names>
</name>
<name>
<surname><![CDATA[Ageno]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating Bleeding Risk in Patients with Cancer Associated Thrombosis Evaluation of Existing Risk Scores and Development of a New Risk Score]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>2022</year>
<volume>122</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>818-29</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahe]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Plaisance]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chapelle]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term treatment of cancer-associated thrombosis (CAT) beyond6 months in the medical practice USCAT, a 432-patient retrospective non-interventional study]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2020</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Kessler]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Goldhaber]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Kovacs]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Monreal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Huisman]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of venous thromboembolism in cancer patints with dalteparin for up to 12 months the DALTECAN Study]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2015</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1028-35</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horsted]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[West]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Grainge]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of venous thromboembolism in patints with cancer a systemati review and meta-analysis]]></article-title>
<source><![CDATA[PLoSMed]]></source>
<year>2012</year>
<volume>9</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soff]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombosis and Hemostasis in Cancer Scope of the Problem and Overview]]></article-title>
<source><![CDATA[Cancer treatment and research]]></source>
<year>2019</year>
<volume>179</volume>
<numero>19</numero>
<issue>19</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oehadian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Iqbal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sumantri]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Deep Vein Thrombosis in Acute Myelogenous Leukemia]]></article-title>
<source><![CDATA[Acta Med Indones]]></source>
<year>2009</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>200-4</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tikhomirova]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Petrochenko]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Malysheva]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ryabov]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kis- lov]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interrelatin of blood coagulatin and hemorheology in cancer]]></article-title>
<source><![CDATA[Clin Hemorheol Microcirc]]></source>
<year>2016</year>
<volume>64</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>635-44</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vedovat]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Giustozzi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bonitt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Agnelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Becatti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficy and safety of antioagulant agents in patints with venous thromboembolism and cancer A network metaanalysis]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2018</year>
<volume>170</volume>
<page-range>175-80</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Potton]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bonadona]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hamidfar-Roy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Somohano]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Lugosi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Venous thromboembolism in the ICU main characteristics, diagnosis and thromboprophylaxis]]></article-title>
<collab>etal</collab>
<source><![CDATA[Crit Care]]></source>
<year>2015</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Casper]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Men]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pendleton]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Kraiss]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[VTEIncidence and Risk Factors in Patients with Severe Sepsis andSeptic Shock]]></article-title>
<collab>etal</collab>
<source><![CDATA[Chest]]></source>
<year>2015</year>
<volume>148</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1224-30</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geerts]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Central venous catheter-related thrombosis]]></article-title>
<source><![CDATA[Hematology Am Soc Hematol Educ Program]]></source>
<year>2014</year>
<volume>2014</volume>
<page-range>306-11</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kekre]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Connors]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[M Venous thromboembolism incidence in hematologic malignancies]]></article-title>
<source><![CDATA[Blood Rev]]></source>
<year>2019</year>
<volume>33</volume>
<page-range>24-32</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mosaad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hassan Elnaem]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cheema]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[AbRahman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer Associated Thrombosis A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies]]></article-title>
<collab>Naila A et al</collab>
<source><![CDATA[Int J Gen Med]]></source>
<year>2021</year>
<volume>14</volume>
<page-range>3881-97</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahajan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wun]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarkers of Cancer-Associated Thromboembolism In Thrombosis and Hemostasis in Cancer]]></article-title>
<source><![CDATA[Cancer Treat Res]]></source>
<year>2019</year>
<volume>179</volume>
<page-range>69-85</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2019</year>
<volume>27</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2507-15</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ruíz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Viñuela]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Aparicio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological cancer treatment and venous thromboembolism risk]]></article-title>
<source><![CDATA[Eur Heart J Suppl]]></source>
<year>2020</year>
<volume>22</volume>
<numero>Suppl C</numero>
<issue>Suppl C</issue>
<page-range>C2-14</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbui]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Finazzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Carobbio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thiele]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Passamonti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rumi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and validation of and International of thrombosis in World Health Organization - essential thrombocythemia (IPSET- thrombosis)]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>120</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>5128-33</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falanga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marchetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schieppati]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms]]></article-title>
<source><![CDATA[Hamostaseologie]]></source>
<year>2021</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-57</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanfilippo]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing the risk of venous thromboembolism in multiple myeloma]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2020</year>
<volume>191</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S74-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Obi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wakefild]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosti biomarkers in venous thromboembolic disease]]></article-title>
<source><![CDATA[J Vasc Surg Venous Lymphat Disord]]></source>
<year>2016</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>508-17</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tilve Gómez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Fernández]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Trillo Fandiño]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Plasencia Martíez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imaging techniques used in the diagnostic workup of acute venous thromboembolic disease]]></article-title>
<source><![CDATA[Radiologic]]></source>
<year>2017</year>
<volume>59</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>329-42</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Sacerio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Basulto]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Batista Hernández]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Acosta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores predictivos de trombosis en pacientes con hemopatías malignas]]></article-title>
<source><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></source>
<year>2017</year>
<volume>33</volume>
<numero>^sSupl</numero>
<issue>^sSupl</issue>
<supplement>Supl</supplement>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia Raso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ene]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Llamas Sillero]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alterations of lipid profile is a risk factor for venous thromboembolism and thrombotic complications]]></article-title>
<source><![CDATA[Eur J Lipid Sci Technol]]></source>
<year>2014</year>
<volume>116</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>514-20</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crous Bou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Harrington]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Kabrhel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Environmental and genetic risk factors associated with venous thromboembolism]]></article-title>
<source><![CDATA[Semin Thromb Hemost]]></source>
<year>2016</year>
<volume>42</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>808-20</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barreto]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Torga]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Nobre]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Main characteristics observed in patients with hematologic diseases admitted to an intensive care unit of a Brazilian university hospital]]></article-title>
<source><![CDATA[Rev Bras Ter Intensiva]]></source>
<year>2015</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>212-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="book">
<collab>Grupo de Coordinación de Expertos</collab>
<source><![CDATA[Trombosis asociada al cáncer (TAC), una causa de muerte muchas veces ignorada en pacientes con cáncer: medidas necesarias para mejorar los resultados en salud y reducir la mortalidad. (Adaptación española del White Paper original)]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Dinamarca ]]></publisher-loc>
<publisher-name><![CDATA[LEO Pharma]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thålin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hisada]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lundström]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mackman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wallén]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neutrophil Extracellular Traps Villains and Targets inArterial, Venous, and Cancer-Associated Thrombosis]]></article-title>
<source><![CDATA[Arterioscler Thromb Vasc Biol]]></source>
<year>2019</year>
<volume>39</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1724-38</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mege]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Aubert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lacroix]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dignat-George]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Panicot-Dubois]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dubois]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Involvement of Platelets in Cancers]]></article-title>
<source><![CDATA[Sem Thromb Hemost]]></source>
<year>2019</year>
<volume>45</volume>
<numero>06</numero>
<issue>06</issue>
<page-range>569-75</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heit]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Spencer]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The epidemiology of venous thromboembolism]]></article-title>
<source><![CDATA[J Thromb Thrombol]]></source>
<year>2016</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-14</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mulder]]></surname>
<given-names><![CDATA[FI]]></given-names>
</name>
<name>
<surname><![CDATA[Candeloro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kamphuisen]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Di Nisio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bossuyt]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Guman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Khorana score for prediction of venous thromboembolism in cancer patients a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Haematologica]]></source>
<year>2019</year>
<volume>104</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1277-87</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prandoni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The treatment of venous thromboembolism in patints with cancer]]></article-title>
<source><![CDATA[Adv Exp Med Biol]]></source>
<year>2017</year>
<volume>906</volume>
<page-range>123-35</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schiffr]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mangu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wade]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Camp-Sorrell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cope]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[El Rayes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Central venous catheter care for the patint with cancer American Society of Clinical oncology clinical practie guideline]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2013</year>
<volume>31</volume>
<page-range>1357-70</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Billingham]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Begum]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Rea]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Warfarin thromboprophylaxis in cancer patints with central venous catheters (WarP) an open-label randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2009</year>
<volume>373</volume>
<page-range>567-74</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Porfiia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Giordano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sturiale]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism a meta-analysis]]></article-title>
<source><![CDATA[Brain Behav]]></source>
<year>2020</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[ZX]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[MX]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Theanti-cancer properties of heparin and its derivatives a reviewand prospect]]></article-title>
<source><![CDATA[Cell ADH Migr]]></source>
<year>2020</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>118-28</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
